The FDA Wants to Inspect Your Factory in One Day. An Algorithm Decides If That's Enough.
The FDA launched an AI-powered pilot that compresses traditional week-long factory inspections into a single day. With nearly 2,000 facilities overdue for routine visits and inspector vacancies at four times pre-pandemic levels, the algorithm is now deciding who gets the speed run and who gets the deep dive.
The Speed Run Nobody Asked For
Imagine you're running a pharmaceutical factory. For decades, an FDA inspection meant bracing for a week-long visit: investigators combing through batch records, walking production floors, interviewing staff, and generally turning your facility inside out for three to seven business days. Now imagine an inspector shows up, spends a single day, and leaves. That's it.
That's exactly what the FDA started doing in April 2026. And the kicker? An AI algorithm helped decide your factory only needed the one-day version.
The agency quietly launched a pilot program for "one-day inspectional assessments," publicly announced on May 6 by Commissioner Marty Makary at the Food and Drug Law Institute conference. The program uses artificial intelligence and risk-based analytics to identify lower-risk facilities, then sends investigators for a condensed, single-day screening visit instead of the traditional multi-day deep dive.
The pilot covers a surprisingly broad swath of FDA territory: human and animal food facilities, biologics manufacturers, medical device makers, drug plants, and even clinical research sites. As of late April, roughly 46 of these one-day assessments had already been completed.
Why Now? Because the Backlog Is Staggering
To understand why the FDA is experimenting with speed inspections, you need to see the numbers behind the curtain. They're ugly.
An Associated Press analysis of FDA data found that nearly 2,000 pharmaceutical manufacturing facilities hadn't been visited for a routine inspection since before the COVID pandemic. That's roughly 42% of the 4,700 sites the agency had previously inspected before May 2019. And that figure is a floor, not a ceiling; it excludes newly registered facilities that have never been inspected at all.
The problem isn't just volume. It's geography. About 160 overdue plants sit in India. Another 185 are in China, where the FDA reportedly has just two full-time inspectors. More than 100 overdue facilities are spread across Mexico, France, and Spain.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
Meanwhile, FDA overall inspection numbers remain well below pre-COVID norms. The agency's internal list of sites needing inspection has actually grown by 14% over the past five years.
So the FDA is stuck in a classic resource trap: more factories to inspect, fewer people to do it, and a backlog that keeps swelling. The one-day pilot is, at its core, a triage strategy.
How the AI Picks Its Targets
Think of it like a credit score for factories. The FDA's algorithm (which references an internal tool called ELSA) evaluates facilities based on several factors: the type of product they make, their compliance history from past inspections, the complexity of their operations, and whether there are discrepancies between what's on their registration and what they actually do.
Facilities that score as lower risk get flagged as candidates for the abbreviated visit. Higher-risk operations, like sterile injectable manufacturing, implantable device production, or advanced cell and gene therapy sites, stay on the traditional inspection track.
This is a crucial distinction. The FDA isn't replacing thorough inspections with quick ones across the board. It's using AI to sort facilities into two buckets: those that probably just need a wellness check, and those that need the full physical.
What a One-Day Visit Actually Looks Like
The "one day" label is slightly misleading. Investigators do substantial homework before they ever set foot in your lobby. They review records, analyze data, and pre-screen risk signals remotely, sometimes over several days. The on-site visit is really a confirmation step: showing up to verify what the data already suggested.
Once there, investigators retain full authority. If they spot something concerning, they can extend the visit beyond one day and expand the scope. Observations get documented on the same FDA Form 483 used in traditional inspections. The legal teeth are identical.
And here's a detail that should make compliance officers sweat: the FDA won't necessarily tell you it's a one-day assessment. You might only realize the visit was abbreviated after the inspector leaves. So every inspection now requires day-one readiness, because you won't know which version you're getting.
Early Results: Mostly Clean Bills of Health
Of the 46 assessments completed through late April, most resulted in "No Action Indicated" classifications, meaning the facilities passed. Some did generate Form 483 observations, and a handful ran longer than one day when investigators found issues worth digging into.
Optimists read this as validation: the AI is correctly identifying low-risk sites. Skeptics wonder if the program is simply being applied to facilities that were already well-run, making the results a self-fulfilling prophecy. The truth probably lives somewhere in between, and the FDA knows it. The agency is tracking escalation rates, inspection duration, and recurring compliance themes specifically to refine the algorithm over time.
What This Means for the Industry
The compliance implications cut in two directions.
For lower-risk manufacturers, the message is deceptively simple: stay clean or lose your status. The AI is watching your track record, your registration accuracy, and your operational profile. A clean compliance history might earn you shorter visits, but a single bad assessment could bump you back into the full-inspection queue and raise your risk score for years.
For higher-risk manufacturers, the math is actually worse. Every abbreviated inspection at a low-risk site frees up an investigator to spend more time at your facility. The pilot doesn't reduce FDA oversight; it redistributes it. Complex biologics plants, sterile manufacturers, and implantable device makers should expect the same (or more) scrutiny, not less.
The broader strategic shift is clear: the FDA is moving from a model where every factory gets roughly the same treatment to one where algorithms allocate regulatory attention based on risk. It's the same logic your health insurer uses when it decides who needs extra screening, applied to pharmaceutical manufacturing.
The Bigger Experiment
The pilot runs through the end of fiscal year 2026 (September 30), and FDA leadership has framed it explicitly as a complement to standard inspections, not a replacement. The agency says enforcement policy hasn't changed: for-cause inspections, routine surveillance, and remote record requests all remain on the table.
But make no mistake about the direction of travel. The FDA is building a data engine. Every one-day assessment generates information that feeds back into the risk models, sharpening future targeting. The 46 completed visits aren't just inspections; they're training data.
Whether you think that's brilliant modernization or a dangerous shortcut probably depends on where your factory falls on the algorithm's risk curve. Either way, the era of one-size-fits-all FDA inspections is ending. The robot is sorting the list now.
5 min read
Astellas Has a $6 Billion Hole in Its Revenue. Here's How It Plans to Fill It.
Astellas Pharma's biggest drug generates over 40% of its revenue and loses U.S. patent protection in 2027. The company just laid out an aggressive plan to buy, partner, and cut its way through the storm, and it's adding serious heat to an already competitive biotech M&A market.
